ACCOuNT is a NIMHD funded Collaborative Consortium aimed at accelerating the pace of pharmacogenomic discovery and translation in African Americans. We are particularly interested in drug used in cardiovascular disease. We have brought together investigators at 2 major US cities (Chicago and DC), as well as clinical, pharmacogenomic and informatics experts to build a sustainable research consortium.
Figure 1. While both the discovery and translational projects are independent efforts, the overall interactions of these projects within ACCOuNT develop a pipeline from which newly discovered SNPs in the Discovery Project and SNPs curated via PharmGKB (Data Analysis and Harmonization Core) can be investigated within Translational Project. Data gather within the Translational Project can inform which drug are relevant candidate for investigation within the Discovery Project. Results of the Translational project will be evaluated by the Implementation Advisory Council (IAC), which will collaborate with regional community partners for implementation planning and pilot project development. The African American genomics database will house information generated via the Discovery Project and will become a resource for the greater pharmacogenomics community. Lastly, all efforts will have oversight for our CSAB within the Consortium core, which will also launch community-based pilot projects.
AA: African American, Dashed arrow show potential synergies, while solid arrows show planned interactions.
AA: African American, Dashed arrow show potential synergies, while solid arrows show planned interactions.
